CERN Accelerating science

Pagina principale > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

Ricerca record 23 per:
Consigli per la Ricerca
Ricerca Avanzata
Add to Search +
Ultimi arrivi:
2019-03-15
16:24
Imaging of iron metabolism
Iron is an essential and critical trace metal in the human body as it is involved in many vital processes like oxygen transport and redox reactions. However, excess iron is toxic and can cause oxidative stress (Dev, 2017). [...]
MED-023.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-15
16:05
Non-invasive imaging of radioactive platinum chemotherapeutics for patient stratification
Platinum containing drugs are chemotherapeutics that are routinely used for cancer treatment in clinics worldwide. The main problems, however, are side effects and treatment resistance due to absent accumulation in tumors (Harper 2010). [...]
MED-022.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-12
18:16
55/161Tb-labeled radioconjugates for cancer therapy with Auger electrons
Auger-emitting radionuclides clinically used for SPECT imaging (e.g. 99mTc, 123I, 67Ga or 111In) started also to be envisaged for selective and targeted radiotherapy. [...]
MED-021.- Geneva : CERN, 2019 - 3. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-12
11:47
Tb-IRMA-V: Terbium ISOL Radioisotopes for Medical Applications in Flanders / Cocolios, Thomas Elias (KU Leuven (BE))
Belgium has a strong tradition in molecular imaging, supported by a lively research community and a broad radioisotope industry (e.g. IBA for the production of cyclotrons, SCK•CEN for the production of 99Mo, IRE for the production of radioisotope generators, …) [...]
MED-020.- Geneva : CERN, 2019 - 3. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-07
15:20
No-carrier-added 175Yb production at MEDICIS from external ILL target
Introduction & background: (state of the art and goal/motivation for the project) High-energy β- emitter 90Y(T1/2 :64 h ; Eβmean = 934 keV) and medium energy β- emitter 177Lu (T1/2: 6.73 d ; Eβ-mean = 154 keV) are the most widely used radionuclides for therapeutic radiopharmaceuticals. Monte Carlo simulations have shown that 177Lu might be more appropriate than 90Y for the treatment of minimal residual disease [1] and practical experience in clinics have proven the favorable properties of 177Lu regarding the significant reduction of undesired side effects to healthy organs (e.g [...]
MED-019.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-07
15:16
No-carrier-added 169Er production at MEDICIS from target irradiated at ILL
Introduction & background: (state of the art and goal/motivation for the project) To date, 169Er (carrier-added) is used for the treatment of chronic rheumatoid arthritis in order to eliminate diseased synovium through irradiation and to improve joint function [1, 2]. However, its decay properties (T1/2 = 9.4 d, Eβmean = 219 keV) are very promising for radionuclide therapy of metastasized cancer diseases. [...]
MED-018.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Record dettagliato - Record simili
2019-03-07
15:13
167Tm production at MEDICIS from external PSI target
Introduction & background: (state of the art and goal/motivation for the project) 167Tm (T1/2 = 9.25 d) is a potential radionuclide both for medical diagnostics and therapy due to its gamma (Eγ = 207.8 keV, I = 42%), and conversion/Auger electron emission (ECE/AE = 5-100 keV, I = 120%) [1]. Previously, 167Tm-citrate was used for tumor imaging using its 207 keV γ-line [2] [...]
MED-017.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Record dettagliato - Record simili
2018-09-24
18:32
Theranostic radiolabeled nanoparticles for ovarian cancer by folate receptor targeting
Patients with epithelial ovarian cancer (EOC) are frequently diagnosed at stage III/IV with widespread peritoneal carcinomatosis, and have a poor overall survival [1]. Because of current screening techniques do not provide early diagnoses of small volume disease, new methods that enhance the detection and treatment of EOC are needed to improve the prognosis of this type of patients. [...]
MED-016.- Geneva : CERN, 2018 - 3. Fulltext: PDF;

Record dettagliato - Record simili
2018-09-24
18:24
44Sc production with 18 MeV cyclotron and study of scandium-labeled peptide based ligands for clinical use
44Sc and 47Sc radionuclides are promising for positron emission tomography (PET/CT) with 44Sc and 47Sc as therapeutic counterpart. It is attractive for theranostic application with 47Sc, 177Lu or 90Y as therapeutic counterparts [1]. [...]
MED-015.- Geneva : CERN, 2018 - 3. Fulltext: PDF;

Record dettagliato - Record simili
2018-09-24
18:15
Labeling of heat-sensitive biomolecules with terbium radionuclides for imaging and treatment of (micro)metastatic CEA-positive colorectal cancer: selecting the optimal match between chelator and radiometal
Colorectal cancer is one of the most frequently diagnosed cancers in the western world and third most common cause of cancer deaths. The use of non-invasive molecular imaging offers the advantage that the entire tumor lesion, as well as possible metastatic lesions can be detected with a single scanning procedure, providing a valuable tool for cancer staging.1 Physiological uptake of [18F]FDG, the most used PET-tracer in oncology, is frequently observed in the gastrointestinal tract, and may complicate the detection of colorectal cancer, in particular peritoneal metastases [...]
MED-014.- Geneva : CERN, 2018 - 4. Fulltext: DOC;

Record dettagliato - Record simili